{"product_id":"biolegend-103127","title":"Biolegend, 103127, Alexa Fluor® 700 anti-mouse CD45 Antibody, 25μg","description":"\u003cp\u003eCD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.\u003cbr\u003e\n25μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: Mouse thymus or spleen\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 700 under optimal conditions.\u003cbr\u003e\nConcentration: 0.5 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested SB - Reported in the literature, not verified in house\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application. * Alexa Fluor® 700 has a maximum emission of 719 nm when it is excited at 633nm \/ 635nm. Prior to using Alexa Fluor® 700 conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome. Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.View full statement regarding label licenses\u003cbr\u003e\nExcitation Laser: Red Laser (633 nm)\u003cbr\u003e\nApplication Notes: Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45. Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin \u0026lt; 0.01 EU\/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).\u003cbr\u003e\nAdditional Product Notes: Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC) Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP) Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC) Seaman WE. 1983. J. Immunol. 130:1713. (CMCD) Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC) Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed Liu F, et al. 2012. Blood. 119:3295. PubMed Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed\u003cbr\u003e\nProduct Citations: Stoupa A, et al. 2018. EMBO Mol Med. 10:. PubMed Komuczki J, et al. 2019. Immunity. 50:1289. PubMed Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed Tomida S, et al. 2019. Sci Rep. 9:10751. PubMed Bohrer AC, et al. 2022. Cell Rep. 40:111144. PubMed Zheng Y, et al. 2022. Proc Natl Acad Sci U S A. 119:e2121077119. PubMed Peng J, et al. 2023. Am J Reprod Immunol. 89:e13678. PubMed Gu J, et al. 2023. J Cell Biochem. 124:557. PubMed Rocca Y, et al. 2023. Methods Mol Biol. 2618:187. PubMed van Elsas MJ, et al. 2023. J Immunother Cancer. 11:. PubMed Senatus L, et al. 2023. Commun Biol. 6:280. PubMed Cai X, et al. 2023. Nat Commun. 14:2004. PubMed Lucas B, et al. 2023. Nat Commun. 14:2066. PubMed Terzic J, et al. 2023. EMBO Mol Med. 15:e17209. PubMed Wang D, et al. 2023. Nat Commun. 14:2943. PubMed Zeng S, et al. 2023. Front Oncol. 13:1171926. PubMed Dong X, et al. 2023. J Transl Med. 21:400. PubMed Miki H, et al. 2020. J Immunol. 204:1892. PubMed Pohlmeier L, et al. 2021. Allergy. 76:2030. PubMed Taranto D, et al. 2021. Curr Protoc. 1:e147. PubMed Yin Q, et al. 2022. J Invest Dermatol. 142:2173. PubMed Paik D, et al. 2022. Nature. 603:907. PubMed van Dierendonck XAMH, et al. 2022. Proc Natl Acad Sci U S A. 119:e2114739119. PubMed Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed Mirchandani AS, et al. 2022. Nat Immunol. 23:927. PubMed Shallberg LA, et al. 2022. PLoS Pathog. 18:e1010296. PubMed Liu H, et al. 2022. Cell Rep Med. 3:100660. PubMed Brown JA, et al. 2022. Gut Microbes. 14:2105609. PubMed Balood M, et al. 2022. Nature. 611:405. PubMed Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed He Y, et al. 2023. Nat Commun. 14:691. PubMed Kraynak CA, et al. 2022. Int J Pharm. 618:121634. PubMed Gomez-Salinero JM, et al. 2022. Cell Stem Cell. 29:593. PubMed Wong Fok Lung T, et al. 2022. Cell Metab. 34:761. PubMed Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed Wong Fok Lung T, et al. 2020. Nat Microbiol. 141:5. PubMed Gonalves S, et al. 2021. Cell Reports. 34(11):108860. PubMed Ren Z, et al. 2021. EMBO Molecular Medicine. :e14059. PubMed Trittel S, et al. 2019. Sci Rep. 9:16362. PubMed Fu R, et al. 2020. Sci Rep. 10:1455. PubMed Guzzi N et al. 2018. Cell. 173(5):1204-1216 . PubMed Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed Ferrere G, et al. 2021. JCI Insight. 6:. PubMed Daskou M, et al. 2022. PLoS Pathog. 18:e1010160. PubMed Jong RM, et al. 2022. J Immunol. 208:407. PubMed Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed Xi H, et al. 2016. J Exp Med. 213: 189 - 207. PubMed Hu X, et al. 2016. Nat Commun. 7:13095. PubMed Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed Gimblet C et al. 2017. Cell host \u0026amp; microbe. 22(1):13-24 . PubMed Putnam NE, et al. 2019. PLoS Pathog. 15:e1007744. PubMed Chen J, et al. 2021. Sci Adv. 7:. PubMed Ghosh S, et al. 2022. APL Bioeng. 6:036105. PubMed Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed Katsura A, et al. 2017. Mol Oncol. 11:1241. PubMed Amir M, et al. 2018. Cell Rep. 25:3733. PubMed Haertel E, et al. 2018. Eur J Immunol. 48:1001. PubMed Tordesillas L, et al. 2018. Nat Commun. 9:5238. PubMed Zhang C, et al. 2022. J Extracell Vesicles. 11:e12209. PubMed Ma C, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed Fujii Y, et al. 2022. JBMR Plus. 6:e10562. PubMed Menzel L, et al. 2021. Cell Rep. 37:109878. PubMed Evren E, et al. 2020. Immunity. 54(2):259-275.e7. PubMed Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed Wang X, et al. 2020. Signal Transduct Target Ther. 5:35. PubMed Egusquiza RJ, et al. 2020. Environ Health Perspect. 128:47011. PubMed McDowell SAC, et al. 2021. Nat Cancer. 2:545. PubMed Reyes RM, et al. 2021. Oncoimmunology. 10:2006529. PubMed Lebratti T, et al. 2021. eLife. 10:00. PubMed Vackova J, et al. 2020. Int J Mol Sci. 21:00. PubMed Yang R, et al. 2012. J Immunol. 189:2656. PubMed Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed Cao W, et al. 2017. Immunity. 47:1182. PubMed van Elsas MJ, et al. 2022. Int J Mol Sci. 23:. PubMed Stutchfield B, et al. 2015. Gastroenterology. 149: 1896-1909.e14. PubMed Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed Sun L, et al. 2020. J Immunol. 2177:204. PubMed Magupalli VG, et al. 2020. Science. :369. PubMed Li J, et al. 2020. Cancer Discov. . PubMed Daubeuf F, et al. 2017. Curr Protoc Mouse Biol. 10.1002\/cpmo.26. PubMed Emgård J, et al. 2018. Immunity. 143:419. PubMed Shan M et al. 2018. Immunity. 49(4):709-724 . PubMed Koliaraki V et al. 2019. Cell reports. 26(3):536-545 . PubMed Sophie Thiemann et al. 2017. Cell host \u0026amp; microbe. 21(6):682-694 . PubMed Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed Tanaka S, et al. 2012. J Immunol. 188:6145. PubMed Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed Fantauzzi MF, et al. 2021. ERJ Open Res. 7: . PubMed Daubeuf F, et al. 2021. Cells. 10:. PubMed An J, et al. 2022. iScience. 25:103570. PubMed Chen ELY, et al. 2021. Cell Rep. 35:109227. PubMed Menzel L, et al. 2022. STAR Protoc. 3:101267. PubMed Abu El Maaty MA, et al. 2022. Sci Adv. 8:eabo2295. PubMed Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed Carozza JA, et al. 2020. Nat Cancer. 184:1. PubMed Levi J, et al. 2020. J Nucl Med. . PubMed Ruhland MK, et al. 2020. Cancer Cell. 37(6):786-799.e5. PubMed Li J, et al. 2020. Cancer Immunol Res. 0.529166667. PubMed Duque-Correa MA, et al. 2022. Nat Commun. 13:1725. PubMed Muñoz NM, et al. 2022. Sci Rep. 12:14449. PubMed He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed Tomlinson KL, et al. 2021. Nat Commun. 12:1399. PubMed Benne N, et al. 2020. Adv Healthc Mater. 9:e2000043. PubMed Prados A, et al. 2021. Nat Immunol. 22:510. PubMed Coursey T, et al. 2016. Mucosal Immunol. 10.1038\/mi.2016.83. PubMed Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed Riquelme SA, et al. 2020. Cell Metabolism. 31(6):1091-1106.e6. PubMed He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed Noah AC, et al. 2020. J Appl Physiol (1985). 473:128. PubMed Hossain DMS, et al. 2018. J Clin Invest. 128:644. PubMed Grzelak A, et al. 2018. Int J Mol Sci. 19:. PubMed Guérin MV, et al. 2019. Nat Commun. 10:4131. PubMed Li J, et al. 2018. Immunity. 49:178. PubMed Garcia LR, et al. 2021. Nat Commun. 12:3364. PubMed Progatzky F, et al. 2021. Nature. 599:125. PubMed Zhao F, et al. 2022. Nat Commun. 13:6117. PubMed McFarland AP, et al. 2021. Immunity. 54(6):1320-1337.e4. PubMed Abboud D, et al. 2015. Sci Rep. 5: 14746. PubMed O'Connor T, et al. 2020. Cancer Cell. 36(3):250-267. PubMed Yadava K et al. 2019. Elife. 8 pii: e44821. PubMed Acker KP, et al. 2019. iScience. 19:281. PubMed Schmid MC, et al. 2022. Nat Commun. 13:1768. PubMed Chen X, et al. 2022. Front Immunol. 13:828319. PubMed He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed Xiong H, et al. 2021. Theranostics. 11:1594. PubMed Frank E, et al. 2016. Toxicol Pathol. 10.1177\/0192623315620587. PubMed Hiebert P et al. 2018. Developmental cell. 46(2):145-161 . PubMed Sitaraman S, et al. 2019. Sci Rep. 9:12509. PubMed Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed Park HB, et al. 2020. Nat Microbiol. 1319:5. PubMed Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed Kostadinova E, et al. 2016. Sci Rep. 6:30943. PubMed Leyva‐Castillo JM et al. 2019. Immunity. 50(5):1262-1275 . PubMed Avraham S, et al. 2019. Oncogene. 38:3812. PubMed Uderhardt S, et al. 2019. Cell. 177:541. PubMed Cohen M et al. 2018. Cell. 175(4):1031-1044 . PubMed Zhang HG, et al. 2022. Cell Res. :. PubMed Zhai K, et al. 2021. Nat Cancer. 2:1136. PubMed Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed Henrich IC, et al. 2021. Cancer Res. 81:2171. PubMed Clark JT, et al. 2021. eLife. 10:00. PubMed Nanou A, et al. 2021. Cell Reports. 35(8):109168. PubMed Ahn D, et al. 2021. Cell Reports. 35(9):109196. PubMed Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed Philip E Boulais et al. 2018. Immunity. 49(4):627-639 . PubMed Crauste F, et al. 2017. Cell Syst. 0.379166667. PubMed Nair S, et al. 2021. JCI Insight. 6:. PubMed Ma J, et al. 2021. J Transl Med. 19:477. PubMed Artham S, et al. 2020. Am J Physiol Lung Cell Mol Physiol. L750:318. PubMed Vacca F, et al. 2020. eLife. 9:e54017.. PubMed Ji G, et al. 2019. Bone Joint J. 101-B:108. PubMed Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed Stevenson ER, et al. 2022. J Pharmacol Exp Ther. 382:356. PubMed Murray MP, et al. 2022. Cell Rep. 38:110209. PubMed Dustin CM, et al. 2021. J Immunol. 206:2989. PubMed Pizzurro GA, et al. 2021. Cancers (Basel). 13:. PubMed Bollenbach M, et al. 2021. Molecules. 26:. PubMed Grajchen E, et al. 2020. J Neuroinflammation. 0.863888889. PubMed Dhar P, et al. 2021. Commun Biol. 4:905. PubMed Abu El Maaty MA, et al. 2021. Sci Adv. 7: . PubMed Zhang MS, et al. 2022. Nat Commun. 13:954. PubMed Liu W, et al. 2022. J Clin Invest. 132: . PubMed Gicheva N, et al. 2016. Biochem Biophys Res Commun. 479:1-4. PubMed Natale CA, et al. 2018. Elife. 7. PubMed Ayturk UM, et al. 2020. J Bone Miner Res. 35:1981. PubMed Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed He X, et al. 2021. J Immunother Cancer. 9:. PubMed Xiao Y, et al. 2021. Cell. 184:6037. PubMed Cambridge E, et al. 2017. Exp Hematol. 45:64-68.e5. PubMed Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed Nicolas-Boluda A, et al. 2021. eLife. 10:00. PubMed Mathewson ND, et al. 2021. Cell. 184(5):1281-1298.e26. PubMed Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed Korin B, et al. 2020. Sleep. :43. PubMed Van der Meer JM, et al. 2020. Cancer Immunol Immunother. . PubMed Molgora M, et al. 2020. Cell. 182:886. PubMed Aguilar-Pimentel A, et al. 2017. PLoS One. 12(6):e0178563. PubMed Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed Hayashida E, et al. 2019. J Neuroinflammation. 0.789583333. PubMed Schaftenaar FH, et al. 2019. Sci Rep. 9:17391. PubMed Zhang Z, et al. 2020. Front Immunol. 11:583276. PubMed Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed Melhem NJ, et al. 2021. Circulation. 143:566. PubMed Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed Hackstein CP, et al. 2022. Nat Commun. 13:7472. PubMed Maulhardt HA, et al. 2020. Invest New Drugs. 1618:38. PubMed Wang M, et al. 2021. iScience. 24(7):102766. PubMed Guey B, et al. 2014. Proc Natl Acad Sci U S A. 111:17254. PubMed Silva HM, et al. 2019. J Exp Med. 216:786. PubMed Hartwig T et al. 2017. Molecular cell. 65(4):730-742 . PubMed Litwinoff EMS, et al. 2017. Obes Res Clin Pract. 12:174. PubMed White JP et al. 2018. Cell. 175(5):1198-1212 . PubMed Dye BR, et al. 2020. Biomaterials. 234:119757. PubMed Lee GR, et al. 2021. JCI Insight. 6:. PubMed Chetty A, et al. 2021. Cell Host Microbe. 29:579. PubMed Maller O, et al. 2020. Nat Mater. 20:548. PubMed Tian F, et al. 2016. Nat Commun. 7:13283. PubMed Sen D, et al. 2016. PLoS One. 11:e0165064. PubMed Peltzer N, et al. 2018. Nature. 557:112. PubMed Miao Y et al. 2019. Cell. 177(5):1172-1186 . PubMed O'Boyle C, et al. 2020. Int J Stroke. 0.746527778. PubMed Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed Gangoso E, et al. 2021. Cell. 184:2454. PubMed Pattabiraman G, et al. 2021. Am J Physiol Renal Physiol. . PubMed Chen Y, et al. 2022. Stem Cells Int. 2022:1309684. PubMed Strait AA, et al. 2021. Commun Biol. 4:1005. PubMed Trivedi S, et al. 2020. Elife. 9:00. PubMed Laczkó D, et al. 2020. Immunity. 53:724. PubMed Harvey RE et al. 2017. Endocrinology. 158(7):2179-2189 . PubMed Wolf Y, et al. 2019. Cell. 179:219. PubMed Riopel M, et al. 2019. Mol Metab. 20:89. PubMed Rossi G, et al. 2022. Sci Rep. 12:13380. PubMed Hohsfield LA, et al. 2021. Elife. 10:. PubMed\u003cbr\u003e\nRRID: AB_493714 (BioLegend Cat. No. 103127) AB_493715 (BioLegend Cat. No. 103128)\u003cbr\u003e\nStructure: Protein tyrosine phosphatase (PTP) family, 180-240 kD\u003cbr\u003e\nDistribution: All hematopoietic cells except mature erythrocytes and platelets\u003cbr\u003e\nFunction: Phosphatase, T and B cell activation\u003cbr\u003e\nLigand\/Receptor: Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1\u003cbr\u003e\nCell Type: B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs\u003cbr\u003e\nBiology Area: Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells\u003cbr\u003e\nMolecular Family: CD Molecules\u003cbr\u003e\nAntigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85. 3. Kishihara K, et al. 1993. Cell 74:143. 4. Pulido R, et al. 1988. J. Immunol. 140:3851.\u003cbr\u003e\nGene ID: 19264\u003cbr\u003e\nUniProt: View information about CD45 on UniProt.org\u003cbr\u003e\nClone: 30-F11\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: T200, Ly-5, LCA\u003cbr\u003e\nIsotype: Rat IgG2b, κ\u003cbr\u003e\nQ: If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?\u003cbr\u003e\nA: It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.\u003cbr\u003e\nQ: Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?\u003cbr\u003e\nA: Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF\/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.\u003cbr\u003e\nQ: Are other fluorophores compatible with IBEX?\u003cbr\u003e\nA: Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.\u003cbr\u003e\nQ: The same antibody works in one tissue type but not another. What is happening?\u003cbr\u003e\nA: Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.\u003cbr\u003e\nQ: How can I be sure the staining I’m seeing in my tissue is real?\u003cbr\u003e\nA: In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46862336196777,"sku":"103127","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/biolegend-103127","provider":"Iright","version":"1.0","type":"link"}